Phase II Study Of Neoadjuvant Chemotherapy With Gemcitabine, Oxaliplatin And Erlotinib (Gemoxt) In Borderline Resectable Pancreatic Adenocarcinoma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 01 May 2009
At a glance
- Drugs Erlotinib; Gemcitabine; Oxaliplatin
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 01 May 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Feb 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 24-Feb-2009.
- 24 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.